Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRSD384 in Overweight or Obese Participants
NCT07557355Phase 2Not yet recruiting
- Sponsor
- Sirius Therapeutics
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SRSD384 in obesity (4 arms), sponsored by Sirius Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events at 168 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SRSD384
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07557355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557355.